208 related articles for article (PubMed ID: 38179049)
1. Making "cold" tumors "hot"- radiotherapy remodels the tumor immune microenvironment of pancreatic cancer to benefit from immunotherapy: a case report.
Tong F; Sun Y; Zhu Y; Sha H; Ni J; Qi L; Gu Q; Zhu C; Xi W; Liu B; Kong W; Du J
Front Immunol; 2023; 14():1277810. PubMed ID: 38179049
[TBL] [Abstract][Full Text] [Related]
2. Mild hyperthermia promotes immune checkpoint blockade-based immunotherapy against metastatic pancreatic cancer using size-adjustable nanoparticles.
Yu Q; Tang X; Zhao W; Qiu Y; He J; Wan D; Li J; Wang X; He X; Liu Y; Li M; Zhang Z; He Q
Acta Biomater; 2021 Oct; 133():244-256. PubMed ID: 34000465
[TBL] [Abstract][Full Text] [Related]
3. [Characteristics of pancreatic ductal adenocarcinoma immune microenvironment and related immunotherapy strategies].
Yuan M; Abuduhaibaier S; Ren SQ; Zheng ZHENG; Yuan CH
Zhonghua Yi Xue Za Zhi; 2021 Mar; 101(12):831-835. PubMed ID: 33789362
[TBL] [Abstract][Full Text] [Related]
4. Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer.
Ye J; Mills BN; Qin SS; Garrett-Larsen J; Murphy JD; Uccello TP; Han BJ; Vrooman TG; Johnston CJ; Lord EM; Belt BA; Linehan DC; Gerber SA
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851308
[TBL] [Abstract][Full Text] [Related]
5. Dilemma and Challenge of Immunotherapy for Pancreatic Cancer.
Wu J; Cai J
Dig Dis Sci; 2021 Feb; 66(2):359-368. PubMed ID: 32140943
[TBL] [Abstract][Full Text] [Related]
6. Durable benefit from immunotherapy and accompanied lupus erythematosus in pancreatic adenocarcinoma with DNA repair deficiency.
Pang X; Qian J; Jin H; Zhang L; Lin L; Wang Y; Lei Y; Zhou Z; Li M; Zhang H
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32636238
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy and Radiotherapy as an Antitumoral Long-Range Weapon-A Partnership with Unsolved Challenges: Dose, Fractionation, Volumes, Therapeutic Sequence.
Mireștean CC; Iancu RI; Iancu DT
Curr Oncol; 2022 Oct; 29(10):7388-7395. PubMed ID: 36290857
[TBL] [Abstract][Full Text] [Related]
8. Hollow Cu2MoS4 nanoparticles loaded with immune checkpoint inhibitors reshape the tumor microenvironment to enhance immunotherapy for pancreatic cancer.
Yao Z; Qi C; Zhang F; Yao H; Wang C; Cao X; Zhao C; Wang Z; Qi M; Yao C; Wang X; Xia H
Acta Biomater; 2024 Jan; 173():365-377. PubMed ID: 37890815
[TBL] [Abstract][Full Text] [Related]
9. Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy.
Li E; Huang X; Zhang G; Liang T
J Exp Clin Cancer Res; 2021 Sep; 40(1):279. PubMed ID: 34479614
[TBL] [Abstract][Full Text] [Related]
10. Advances in immunotherapy for pancreatic ductal adenocarcinoma.
Miyazawa M; Katsuda M; Kawai M; Hirono S; Okada KI; Kitahata Y; Yamaue H
J Hepatobiliary Pancreat Sci; 2021 May; 28(5):419-430. PubMed ID: 33742512
[TBL] [Abstract][Full Text] [Related]
11. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
[TBL] [Abstract][Full Text] [Related]
12. Overcoming the resistance of pancreatic cancer to immune checkpoint inhibitors.
Skelton RA; Javed A; Zheng L; He J
J Surg Oncol; 2017 Jul; 116(1):55-62. PubMed ID: 28628715
[TBL] [Abstract][Full Text] [Related]
13. Synergistic interventional photothermal therapy and immunotherapy using an iron oxide nanoplatform for the treatment of pancreatic cancer.
Wang M; Li Y; Wang M; Liu K; Hoover AR; Li M; Towner RA; Mukherjee P; Zhou F; Qu J; Chen WR
Acta Biomater; 2022 Jan; 138():453-462. PubMed ID: 34757232
[TBL] [Abstract][Full Text] [Related]
14. Combination immunotherapy for pancreatic cancer: challenges and future considerations.
Gössling GCL; Zhen DB; Pillarisetty VG; Chiorean EG
Expert Rev Clin Immunol; 2022 Nov; 18(11):1173-1186. PubMed ID: 36045547
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy analysis of PD-1 inhibitors in combination with chemotherapy for advanced pancreatic cancer.
Song D; Yang X; Guo X; Sun H
Immunotherapy; 2022 Nov; 14(16):1307-1313. PubMed ID: 36341552
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of pancreatic cancer.
Sunami Y; Kleeff J
Prog Mol Biol Transl Sci; 2019; 164():189-216. PubMed ID: 31383405
[TBL] [Abstract][Full Text] [Related]
17. Pyroptosis Remodeling Tumor Microenvironment to Enhance Pancreatic Cancer Immunotherapy Driven by Membrane Anchoring Photosensitizer.
Wang M; Wu M; Liu X; Shao S; Huang J; Liu B; Liang T
Adv Sci (Weinh); 2022 Oct; 9(29):e2202914. PubMed ID: 35981886
[TBL] [Abstract][Full Text] [Related]
18. Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice.
Smith JP; Wang S; Nadella S; Jablonski SA; Weiner LM
Cancer Immunol Immunother; 2018 Feb; 67(2):195-207. PubMed ID: 29043413
[TBL] [Abstract][Full Text] [Related]
19. Immunologic Strategies in Pancreatic Cancer: Making
Ullman NA; Burchard PR; Dunne RF; Linehan DC
J Clin Oncol; 2022 Aug; 40(24):2789-2805. PubMed ID: 35839445
[TBL] [Abstract][Full Text] [Related]
20. Synergies Radiotherapy-Immunotherapy in Head and Neck Cancers. A New Concept for Radiotherapy Target Volumes-"Immunological Dose Painting".
Mireştean CC; Crişan A; Buzea C; Iancu RI; Iancu DT
Medicina (Kaunas); 2020 Dec; 57(1):. PubMed ID: 33374739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
